Article
NTBC dosing and outcomes in hereditary tyrosinemia type 1: insights from a representative human model and 99 patients
2025-10-07
Abstract excerpt
Hereditary tyrosinemia type 1 (HT1) is a rare and severe metabolic liver disorder caused by fumarylacetoacetate hydrolase (FAH) deficiency. The optimal dose and long-term effects of the only available treatment, nitisinone (NTBC), remain unclear due to the absence of clinical trial data. Here, we generated a representative human in vitro model of HT1 using iPSC-derived hepatocytes, which faithfully recapitulated k...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 5ba801fe-d269-5550-8266-43e289e50593
- DOI
- 10.1101/2025.10.06.680797
